192 related articles for article (PubMed ID: 17825982)
1. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Pouessel D; Culine S
Eur Urol; 2008 Feb; 53(2):376-81. PubMed ID: 17825982
[TBL] [Abstract][Full Text] [Related]
2. Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81.
Porta C; Imarisio I; Paglino C
Eur Urol; 2008 May; 53(5):1092-3. PubMed ID: 18160205
[No Abstract] [Full Text] [Related]
3. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Lee JL; Park I; Park K; Park S; Ahn Y; Ahn JH; Kim TW; Ahn S; Song C; Hong JH; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2012 Apr; 138(4):687-93. PubMed ID: 22237457
[TBL] [Abstract][Full Text] [Related]
7. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
8. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
9. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Hill KL; Lipson AC; Sheehan JM
J Neurosurg; 2009 Sep; 111(3):497-503. PubMed ID: 19199506
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Rini BI; Choueiri TK; Elson P; Khasawneh MK; Cotta C; Unnithan J; Wood L; Mekhail T; Garcia J; Dreicer R; Bukowski RM
Cancer; 2008 Sep; 113(6):1309-14. PubMed ID: 18618496
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
12. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Ravaud A; Digue L; Trufflandier N; Smith D
Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
[No Abstract] [Full Text] [Related]
13. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
15. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Ravaud A; Sire M
Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
[No Abstract] [Full Text] [Related]
16. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
17. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Berchem G; Dewilde S; Mahassen P
Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Vickers MM; Al-Harbi H; Choueiri TK; Kollmannsberger C; North S; MacKenzie M; Knox JJ; Rini BI; Heng DY
Clin Genitourin Cancer; 2013 Sep; 11(3):311-5. PubMed ID: 23684422
[TBL] [Abstract][Full Text] [Related]
19. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
20. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
[Next] [New Search]
